Hanson & Doremus Investment Management grew its stake in Pfizer Inc. (NYSE:PFE) by 1.7% during the 4th quarter, HoldingsChannel reports. The firm owned 119,046 shares of the biopharmaceutical company’s stock after buying an additional 1,987 shares during the quarter. Pfizer accounts for about 1.3% of Hanson & Doremus Investment Management’s investment portfolio, making the stock its 12th biggest holding. Hanson & Doremus Investment Management’s holdings in Pfizer were worth $4,664,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. 1 North Wealth Services LLC purchased a new stake in shares of Pfizer during the third quarter worth approximately $29,000. Salomon & Ludwin LLC lifted its holdings in Pfizer by 362.7% in the 3rd quarter. Salomon & Ludwin LLC now owns 893 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 700 shares in the last quarter. Bourgeon Capital Management LLC purchased a new position in Pfizer in the 3rd quarter valued at $32,000. B & T Capital Management DBA Alpha Capital Management purchased a new position in Pfizer in the 3rd quarter valued at $36,000. Finally, Sageworth Trust Co purchased a new position in Pfizer in the 3rd quarter valued at $44,000. 70.21% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have weighed in on the company. JPMorgan Chase & Co. restated a “neutral” rating on shares of Pfizer in a report on Tuesday, October 29th. Royal Bank of Canada assumed coverage on Pfizer in a research note on Monday, January 6th. They issued an “outperform” rating and a $46.00 target price for the company. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Bank of America assumed coverage on Pfizer in a research note on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 target price for the company. Finally, Zacks Investment Research raised Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 target price for the company in a research note on Tuesday, October 1st. Nine investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $43.41.
PFE traded down $0.20 during trading hours on Thursday, reaching $40.47. The company’s stock had a trading volume of 5,463,485 shares, compared to its average volume of 16,200,954. Pfizer Inc. has a fifty-two week low of $33.97 and a fifty-two week high of $44.56. The stock has a market cap of $221.75 billion, a PE ratio of 13.49, a P/E/G ratio of 4.24 and a beta of 0.65. The business’s 50-day moving average is $38.90 and its 200-day moving average is $38.18. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.90 and a quick ratio of 0.68.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.13. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. The firm had revenue of $12.68 billion for the quarter, compared to analysts’ expectations of $12.37 billion. During the same period in the prior year, the firm posted $0.78 earnings per share. The firm’s quarterly revenue was down 4.6% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.97 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 31st will be issued a $0.38 dividend. The ex-dividend date is Thursday, January 30th. This is a boost from Pfizer’s previous quarterly dividend of $0.36. This represents a $1.52 dividend on an annualized basis and a yield of 3.76%. Pfizer’s dividend payout ratio is currently 48.00%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
See Also: What are some reasons analysts would give stocks a buy rating?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.